NCT04105959

A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Model

A Randomised, Single-Blind, Placebo-Controlled, Crossover Study to Investigate the Effects of RIST4721, a Novel CXCR2 Inhibitor, on the Inflammatory Response in Healthy Male Subjects Using a Standardized Blister Model

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Aristea Therapeutics, Inc. · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A Randomised, Single-Blind, Placebo-Controlled, Crossover Study to Investigate the Effects of RIST4721, a Novel CXCR2 Inhibitor, on the Inflammatory Response in Healthy Male Subjects Using a Standardized Blister Model

Conditions

• Inflammatory Response

Interventions

Type	Name	Description
DRUG	RIST4721	RIST4721 oral solution
DRUG	Placebo	Placebo oral solution

Timeline

• Start date: 2019-07-25
• Primary completion: 2019-11-19
• Completion: 2019-12-09
• First posted: 2019-09-26
• Last updated: 2020-06-29

Locations

1 site across 1 country: United Kingdom